“ Of note, relatively low concentrations of monepantel blocked the infectious capacity of SARS-CoV-2 in tissue culture “
Re Questions : Covid trial
Q/ How achievable is it that Pharmaust will succeed with tolerable monepantel concentration levels in human trials to block the infectious capacity of SARS-CoV-2 , and if achievable , will this place the medical world spotlight directly upon us as a viable solution to combat both , the level of spread in community and level of effect on the individual , will we replace some of the early front runners who have stumbled due to unachievable concentration levels in humans ?
Ann: Virtual Investor Briefing, page-37
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.5¢ |
Change
-0.005(2.38%) |
Mkt cap ! $91.22M | |||
| Open | High | Low | Value | Volume |
| 21.5¢ | 21.5¢ | 20.5¢ | $174.5K | 841.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 458470 | 20.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.0¢ | 144453 | 3 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| PAA (ASX) Chart |